Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MBD2
REST API REST API
Homo sapiens
MBD2 is differentially expressed in 322 experiments: 185 organism parts: lung, cerebellum, ... (183 more);, 254 disease states: normal, glioblastoma, ... (252 more);, 113 cell types 426 cell lines 42 compound treatments and 79 other conditions.
Orthologs D3ZXG8_RAT (Rattus norvegicus)   MBD2 (Bos taurus)   Mbd2 (Mus musculus)   MBD-like (Drosophila melanogaster)   mbd2 (Xenopus laevis)   MBD2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, histone deacetylase complex, siRNA binding, cytoplasm, regulation of cell proliferation, protein domain specific binding, methyl-CpG binding, heterochromatin, mRNA binding, nucleus, satellite DNA binding, chromatin binding, chromatin, negative regulation of transcription from RNA polymerase II promoter, positive regulation of Wnt receptor signaling pathway, cellular protein complex assembly, C2H2 zinc finger domain binding, maternal behavior
InterPro Term Methyl_CpG_DNA-bd
UniProt Accession Q9UBB5, Q69YZ5, O60535
Search EB-eye ENSG00000134046
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-TABM-420, E-GEOD-14990
PC3
2
E-MEXP-2034, E-GEOD-5258
primary culture
2
E-GEOD-2450, E-GEOD-1657
420 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (51 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18147, E-GEOD-20033, E-GEOD-18265
endothelial cell
1
3
E-GEOD-19240, E-GEOD-96, E-GEOD-3920, E-GEOD-3998
centroblast
2
E-GEOD-15271, E-TABM-702
CD105+ endothelial
2
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
107 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-GEOD-12254, E-GEOD-16363, E-MTAB-62, ... (69 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-5377
glioblastoma
1
3
E-GEOD-4290, E-GEOD-6014, E-MTAB-62, E-MEXP-567
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
248 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-GEOD-697, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
chloroguine
1
E-GEOD-5418
TGF
1
E-GEOD-15205
poly(I:C)
1
E-MEXP-1230
U0126
1
E-GEOD-697
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
36 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
53
2
1
E-GEOD-3494
80 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, E-GEOD-2666, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-MTAB-69, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (6 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, E-TABM-601, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-TABM-127, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-22541, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541

Vehicle
studied in E-GEOD-5258

Processing time: 0.37 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM